{"id":390837,"date":"2017-11-28T00:00:00","date_gmt":"2017-11-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0007-2017-biopharma-non-small-cell-lung-cancer-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-04-21T05:27:44","modified_gmt":"2026-04-21T05:27:44","slug":"dlsfon0007-2017-biopharma-non-small-cell-lung-cancer-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0007-2017-biopharma-non-small-cell-lung-cancer-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p>NSCLC has one of the most dynamic drug development pipelines in oncology, including multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust growth throughout the 2016-2026 forecast period. The biggest driver of market sales growth will be the continued uptake and anticipated label expansions of immune checkpoint inhibitors. Merck &#038; ;s Keytruda became the first immune checkpoint inhibitor to receive approval for first-line NSCLC and is anticipated to generate significant sales in this setting. EGFR and ALK inhibitor drug classes will also contribute to market growth following the first-line label expansions of Tagrisso and Alecensa, respectively. Several new therapies will gain approvals within the forecast period, from four different drug classes, resulting in increased therapy options and a highly competitive market.\u00a0<br \/>\n<strong>Questions Answered\u00a0<\/strong><\/p>\n<ul>\n<li>How large are the drug-treatable NSCLC populations and how will the drug-treatment rates change over time?\u00a0<\/li>\n<li>What is the current state of treatment in NSCLC ? What are interviewed experts\u2019 insights on current treatment options?\u00a0 What clinical needs remain unfulfilled?\u00a0<\/li>\n<li>How will different immune checkpoint inhibitor regimens compete in the first-line metastatic NSCLC setting? What will patient share dynamics look like in high PD-L1 \u00a0( TPS \u00a0\u226550%) and negative\/low- PD-L1 patient segments?\u00a0<\/li>\n<li>What will be the therapy options for EGFR &#8211; and ALK -positive patients\u00a0following progression on first-line Tagrisso\u00a0and Alecensa, respectively?\u00a0<\/li>\n<li>What pipeline products are most promising, and what sales\/uptake could they secure in NSCLC ? What therapies of note are progressing in earlier phases?\u00a0<\/li>\n<li>What are the drivers and constraints in the NSCLC market, and how will the market evolve over the forecast period?\u00a0<\/li>\n<\/ul>\n<p>\n<strong>Product Description\u00a0<\/strong><br \/>\nDisease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.\u00a0<\/p>\n","protected":false},"template":"","class_list":["post-390837","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390837\/revisions"}],"predecessor-version":[{"id":576789,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390837\/revisions\/576789"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}